City of Hope | Strategic Alliance Partners

May 19, 2022

Erminia Massarelli, MD, PhD, MS, discusses advances in front-line immunotherapy in non–small cell lung cancer.

May 16, 2022

Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab plus axitinib for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.

May 12, 2022

Edward Kim, MD, MBA, discussed the facets of each presentation from the meeting, featuring other emerging targeted therapies in NSCLC, biomarker testing in the space, frontline immunotherapy in NSCLC, and the current management of small cell lung cancer.

April 28, 2022

Institutional Perspectives in Cancer- Precision Medicine-Lung: Chaired by Edward Kim, MD, MBA

April 19, 2022

Afsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.

March 24, 2022

Pamela S. Becker, MD, PhD, discusses the rationale for investigating uproleselan in combination with chemotherapy in relapsed/refractory acute myeloid leukemia.

March 24, 2022

Dr Barzi discusses data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with colorectal cancer, results from an investigation of nivolumab plus ipilimumab for patients with high tumor mutational burden, and more.

March 21, 2022

Afsaneh Barzi, MD, PhD, discusses the safety and efficacy of regorafenib in combination with pembrolizumab in patients with MSS colorectal cancer and describes potential next steps for further exploration of novel combinations in this population.

March 17, 2022

Haris Ali, MD, discusses updates in acute and chronic graft-vs-host-disease, current and emerging agents in myelofibrosis and polycythemia vera, and chronic lymphocytic leukemia management.

March 17, 2022

“I still have about 250 active patients with blood cancers, and every single one has my cell phone. I do everything in real time....That connection is very important and meaningful for me.”

February 28, 2022

February 24, 2022

Afsaneh Barzi, MD, PhD, discusses the combination of VEGF inhibitors and immunotherapy in microsatellite stable metastatic colorectal cancer.

February 18, 2022

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

February 13, 2022

Joanne Mortimer, MD, discusses current applications for HER2-directed antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors in early-stage and metastatic breast cancer.

February 10, 2022

The organizations join forces to become one of the largest cancer research and treatment organizations in the country.

January 26, 2022

Afsaneh Barzi, MD, PhD, discusses the importance of developing novel therapies in metastatic colorectal cancer.

January 22, 2022

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

January 14, 2022

Joanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.

January 14, 2022

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.

January 13, 2022